Patents Represented by Attorney, Agent or Law Firm Norbert F. Reinert
  • Oxime ethers as IIb/IIa antagonists
    Patent number: 6348504
    Abstract: This invention relates generally to oxime ethers which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: February 19, 2002
    Inventors: Richard E. Olson, William E. Frietze
  • Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors
    Patent number: 6235733
    Abstract: A palatable oral liquid pharmaceutical composition of benzoxazinone compounds useful as HIV reverse transcriptase inhibitors comprising the benzoxazinone active ingredient in a liquid vehicle comprising medium chain fatty acid triglycerides. Other formulating agents such as sweetening agents, lecithin suspending agents, etc. may be optionally added.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: May 22, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Surendra M. Bahal, Michael B. Maurin
  • 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles as .alpha..sub.v .beta..sub.3 antagonists
    Patent number: 6153628
    Abstract: This invention relates to 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles of Formula (I) which are useful as antagonists of .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the tretment of angioginic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: November 28, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Fuqiang Jin, Pasquale N. Confalone
  • Isoxazoline and isoxazole fibrogen receptor antagonists
    Patent number: 6114328
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 5, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
    Patent number: 6060462
    Abstract: This invention relates to electrophilic dipeptide analogs conjugated to an N,N-disubstituted .alpha.-amino acid as inhibitors of trypsin-like serine protease enzymes.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: May 9, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert Anthony Galemmo, Jr., Matthew Mark Abelman, Eugene Cruz Amparo, John Matthew Fevig, Robert Madara Knabb, William Henry Miller, Gregory James Pacofsky, Patricia Carol Weber, Joseph Cacciola
  • Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
    Patent number: 6004955
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: December 21, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Fuqiang Jin, Pasquale Nicholas Confalone
  • Removal of boronic acid protecting groups by transesterification
    Patent number: 5384410
    Abstract: A method for the removal of ester protecting groups from .alpha.-amino boronic acid is disclosed for the preparation of compounds of formula (II) belowR.sup.1 -X.sub.n -NHCH (R.sup.2)-B(OH).sub.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: January 24, 1995
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventor: Charles A. Kettner
  • Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
    Patent number: 5376666
    Abstract: Novel heterocycle substituted azocycloalkane benzylimidazoles of Formula (I), which are useful as angiotensin-II antagonists, are disclosed: ##STR1##
    Type: Grant
    Filed: November 30, 1992
    Date of Patent: December 27, 1994
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventor: John J. V. Duncia
  • (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
    Patent number: 5280037
    Abstract: (Benzimidazol-1'-ymethyl)phenylacetaldehydes as Topical Anti-inflammatories.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: January 18, 1994
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventor: Joseph J. Petraitis
  • (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
    Patent number: 5272169
    Abstract: (Indazol-1'-ymethyl)phenylacetaldehydes as Topical Anti-inflammatories.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: December 21, 1993
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventor: Joseph J. Petraitis